NCT02068365

An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy

CompletedPHASE4INTERVENTIONAL

Trial Details

Start: 2013-06Est. Completion: 2019-06

Enrollment target: 41 participants

Locations

Chronic Hepaititis B

This is an open-label study with single- and multiple-ascending dose arms followed by a dose expansion arm. The primary …

Lyon, FranceEst. completion Dec 31, 2032

Chronic Hepaititis B Infections

This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 sub…

Orlando, United StatesEst. completion Apr 20, 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.